Oncoproteomic profiling with antibody microarrays 英文参考文献.docVIP

Review Oncoproteomic profiling with antibody microarrays Mohamed SS Alhamdani, Christoph Schr?der and J?rg D Hoheisel Address: Division of Functional Genome Analysis, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 580, D-69120 Heidelberg, Germany. Correspondence: Mohamed Saiel Saeed Alhamdani. Email: m.alhamdani@dkfz-heidelberg.de diagnosis. required that enhance the power of detection and diagnosis of cancer at early stages. In consequence, approaches are urgently Abstract The incidence of cancer and its associated mortality are increasing globally, indicating an urgent need to develop even more effective and sensitive sets of biomarkers that could help in early diagnosis and consequent intervention. Given that many cellular processes are carried out by proteins, cancer research has recently shifted toward an exploration of the full proteome for such discovery. Among the advanced methodologies that are being developed for analyzing the proteome, antibody microarrays have become a prominent tool for gathering the information required for a better understanding of disease biology, early detection, discrimination of tumors and monitoring of disease progression. Here, we review the technical aspects and challenges in the development and use of antibody microarray assays and examine recently reported applications in oncoproteomics. Prompted by the sequencing of the human genome, high- throughput technologies have evolved, shifting attention towards a non-reductionist approach to investigating biological phenomena. The explosion of interest in exploring the genome and proteome for biomarkers has already provided a better understanding of the molecular basis of cancer. Among the high-throughput technologies, DNA analysis by microarrays [2] and, more recently, second-generation sequencing [3] have